Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in hospitalized COVID-19 patients
IRCT20151227025726N29Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in coronavirus pneumonia, sponsored by Iran University of Medical Sciences. Primary endpoints: Chest CT scan result, ICU hospitalization need and duration and 3 more. Started Feb 2022; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on IRCT20151227025726N29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151227025726N29.